Roche announced it will present over 30 abstracts on various cancers at the ESMO Congress 2025. These presentations highlight Roche's commitment to developing impactful cancer treatments, especially for breast, lung, and gastrointestinal cancers. A key presentation will feature giredestrant, showing positive results in advanced breast cancer. Tecentriq data from the IMvigor011 trial will be presented, showing improved outcomes in bladder cancer. Final overall survival data from the ALEX study of Alecensa for ALK-positive NSCLC will be released. Updated results from the ALINA study on adjuvant Alecensa in early-stage NSCLC will also be showcased. These data emphasize the importance of Roche's medicines in treating various cancer types. The company is actively researching innovative therapies and combinations. Roche continues to focus on precision medicine and aims to improve cancer outcomes. The presentations reflect Roche's commitment to personalized healthcare.